Abstract
The identification of the cellular targets of small‐molecule protein kinase inhibitors is a significant hurdle to assessing their therapeutic potential for many diseases. Here we review several biochemical and genetics‐based approaches to identifying inhibitor targets. We also describe a chemical‐genomics approach to kinase‐inhibitor target identification and validation that matches transcriptional signatures elicited by a drug of unknown specificity and those elicited by highly specific pharmacological inhibition of engineered candidate kinase targets.